Related Experiment Video

Updated: Apr 11, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.6K

[Gut microbiota-associated metabolites with drug-induced liver injury]

W K Gao1, S Q Yan2, J K Che2

  • 1Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, State Key Clinical Specialty of Critical Care Medicine, Hubei Clinical Research Center of Critical Care Medicine, Wuhan 430071, China.

Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology
|April 9, 2026
PubMed

Insights

Drug-induced liver injury (DILI) involves gut microbiota imbalances. Targeting gut metabolites offers a promising new approach for DILI diagnosis and treatment, improving patient outcomes.

Area of Science:

  • Hepatology
  • Microbiology
  • Pharmacology

Background:

  • Drug-induced liver injury (DILI) presents diverse clinical patterns and lacks specific treatments.
  • DILI incidence is increasing globally, posing a significant public health challenge.
  • The gut-liver axis and gut microbiota's role in DILI are gaining attention.

Purpose of the Study:

  • To review the impact of microbiota-associated metabolites on DILI.
  • To explore the clinical potential of gut microbiota and metabolite interventions for DILI.
  • To provide a theoretical basis for understanding DILI pathogenesis and developing novel strategies.

Main Methods:

  • Literature review focusing on DILI and gut microbiota.
  • Analysis of studies investigating gut microbial ecology in DILI patients.
  • Examination of metabolite profiles and their association with DILI.

Main Results:

  • DILI patients exhibit gut microbial dysbiosis and altered metabolite levels (e.g., LPS, bile acids, SCFAs).
  • Gut microbiota metabolites influence DILI pathogenesis via the gut-liver axis.
  • Specific microbial populations and their metabolites are implicated in DILI progression.

Conclusions:

  • Gut microbiota-targeted regulation and metabolite intervention are potential novel therapeutic strategies for DILI.
  • Understanding microbiota-associated metabolites can enhance DILI diagnosis and treatment.
  • Further research into the gut-liver axis is crucial for advancing DILI management.

More Related Videos

An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products14:54

An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products

Published on: October 20, 2018

9.0K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.9K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
321
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
261
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
345
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
372
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
4.3K
Drug Biotransformation: Overview01:28

Drug Biotransformation: Overview

Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
6.3K